| VERACYTE INC. DL-,001 |
| USA |
| Gesundheit |
| US92337F1075 / A1W7EA |
| 12V (Frankfurt) / VCYT (NASDAQ) |
| FRA:12V, ETR:12V, 12V:GR, NASDAQ:VCYT |
| - |
| https://www.veracyte.com/ |
|
Veracyte, Inc. is a precision diagnostics company that develops genomic tests to help clinicians answer critical questions in cancer and other diseases. Veracyte’s current portfolio includes laboratory-developed tests for thyroid, prostate, bladder..
>Volltext.. |
| 3206.06 Mio. EUR |
| 2816.81 Mio. EUR |
| 493.27 Mio. EUR |
| 103.24 Mio. EUR |
| 100.5 Mio. EUR |
| 1.27 EUR |
| 35.21 Mio. EUR |
| 262.94 Mio. EUR |
| 156.59 Mio. EUR |
| 7.73 |
| 20.96% |
| 348.39% |
| - |
| - |
| - |
| 6 Insider verkauften innerhalb der letzten 30 Tage Aktien im Wert von 1.147.760 Euro. |
| VERACYTE |
| 26.09.26 |
|